Antigen Discovery wins SBIR award
The three-year, $2.5m award is a continuation to phase I SBIR grant to scan the Plasmodium falciparum proteome for protective antigens. As part of the research, ADi proteome
AstraZeneca and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have signed an exclusive licence agreement for TQC3721.